1. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
- Author
-
Verschraagen M, Boven E, Zegers I, Hausheer FH, and Van der Vijgh WJ
- Subjects
- Adult, Antineoplastic Agents pharmacology, Area Under Curve, Chromatography, High Pressure Liquid, Cisplatin pharmacology, Electrochemistry, Half-Life, Humans, Male, Mesna blood, Ascites metabolism, Mesna analogs & derivatives, Mesna pharmacokinetics
- Abstract
Purpose: BNP7787 (2',2'-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin., Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode., Results: After the i.v. administration of 41 g/m(2) BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The AUC( infinity ) of mesna was approximately 8% of the AUC( infinity ) of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration., Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmacokinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.
- Published
- 2003
- Full Text
- View/download PDF